Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Mature B-cell neoplasms, particularly diffuse large B-cell lymphoma (DLBCL), are common non-Hodgkin lymphomas.
• Multiparameter flow cytometry (MFC) offers a rapid and economical method for assessing lymphoid markers in these conditions.

Purpose of the Study:

• To establish a robust algorithm for DLBCL cell line authentication using MFC.
• To develop a gene expression-based risk score for predicting DLBCL patient outcomes.
• To explore the correlation between specific marker expression and treatment resistance in DLBCL.

Main Methods:

• MFC was used to characterize 27 lymphoid markers in 16 DLBCL cell lines.
• A risk score was developed based on the expression of BCL2, BCL6, CD11c, and LAIR1 genes in DLBCL samples.
• DLBCL cell line responses to cyclophosphamide, etoposide, doxorubicin, and gemcitabine were evaluated.

Main Results:

• A robust MFC algorithm for DLBCL cell line authentication was established.
• The gene expression-based risk score effectively stratified DLBCL patients into four risk groups.
• The risk score independently predicted overall survival and showed a correlation between BCL6 overexpression and etoposide resistance.

Conclusions:

• MFC is valuable for routine characterization of DLBCL cells and tumors for research and clinical purposes.
• The developed risk score offers a novel prognostic tool for DLBCL patients.
• Findings suggest potential links between specific marker expression and therapeutic response, guiding future treatment strategies.